{"DataElement":{"publicId":"5732950","version":"1","preferredName":"Crizotinib Agent Administered Formulation Descriptive Type","preferredDefinition":"Information related to the type of Crizotinib agent formulation administered.","longName":"CRIZ_ADMT_AGT_FRM_DESC_TYP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5731692","version":"1","preferredName":"Crizotinib Agent Administered","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The act of having given something (e.g., a medication or test).","longName":"5731690v1.0:2233610v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5731690","version":"1","preferredName":"Crizotinib Agent","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C74061:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C213504-F0E4-65FC-E053-F662850A793C","latestVersionIndicator":"Yes","beginDate":"2017-04-01","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-01","modifiedBy":"ONEDATA","dateModified":"2017-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C213504-F0F2-65FC-E053-F662850A793C","latestVersionIndicator":"Yes","beginDate":"2017-04-01","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-01","modifiedBy":"MAESKEB","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5796804","version":"1","preferredName":"Agent Formulation Descriptive Type","preferredDefinition":"All text that describes the formulation of the agent used in the study._Something distinguishable as an identifiable class based on common qualities.","longName":"5796804v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Both","valueDescription":"Both","ValueMeaning":{"publicId":"5612442","version":"1","preferredName":"Both","longName":"5612442","preferredDefinition":"One and the other; relating to or being two in conjunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Both","conceptCode":"C49636","definition":"One and the other; relating to or being two in conjunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"453584A6-3600-15AA-E053-F662850A2541","latestVersionIndicator":"Yes","beginDate":"2017-01-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-01-03","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E41835B-2F84-6E12-E053-F662850ABE95","beginDate":"2017-04-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-28","modifiedBy":"ONEDATA","dateModified":"2017-04-28","deletedIndicator":"No"},{"value":"Formulated Capsule","valueDescription":"Capsule Dosage Form","ValueMeaning":{"publicId":"5796808","version":"1","preferredName":"Capsule Dosage Form","longName":"5796808","preferredDefinition":"A solid contained within either a hard or soft soluble shell, usually prepared from gelatin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capsule Dosage Form","conceptCode":"C25158","definition":"A solid contained within either a hard or soft soluble shell, usually prepared from gelatin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E41835B-2FB4-6E12-E053-F662850ABE95","latestVersionIndicator":"Yes","beginDate":"2017-04-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E41835B-2FCD-6E12-E053-F662850ABE95","beginDate":"2017-04-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-28","modifiedBy":"ONEDATA","dateModified":"2017-04-28","deletedIndicator":"No"},{"value":"Oral solution","valueDescription":"Oral Route of Administration Solution Dosage Form","ValueMeaning":{"publicId":"5796807","version":"1","preferredName":"Oral Route of Administration Solution Dosage Form","longName":"5796807","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: A liquid preparation that contains one or more chemical substances dissolved, i.e., molecularly dispersed, in a suitable solvent or mixture of mutually miscible solvents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Solution Dosage Form","conceptCode":"C42986","definition":"A clear, homogeneous liquid composed of one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E41835B-2F91-6E12-E053-F662850ABE95","latestVersionIndicator":"Yes","beginDate":"2017-04-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E41835B-2FAA-6E12-E053-F662850ABE95","beginDate":"2017-04-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-28","modifiedBy":"ONEDATA","dateModified":"2017-04-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E41835B-2F55-6E12-E053-F662850ABE95","latestVersionIndicator":"Yes","beginDate":"2017-04-28","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-28","modifiedBy":"LAMEMIL","dateModified":"2021-12-29","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18 Updated max length EL 12/29/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Formulation of Crizotinib adm","type":"Preferred Question Text","description":"Formulation of Crizotinib administered:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C5D5F35-5032-2BA6-E053-F662850A1B81","latestVersionIndicator":"Yes","beginDate":"2017-04-04","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-04","modifiedBy":"FEIBUSHL","dateModified":"2022-01-27","changeDescription":"updated VD to new VD. JWD Revised definition LF 01/27/2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}